These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34960240)

  • 1. Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population.
    Papadopoli R; De Sarro C; Palleria C; Gallelli L; Pileggi C; De Sarro G
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
    Stellini R; Gianello R; Gomarasca W
    Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.
    Franzese M; Coppola L; Silva R; Santini SA; Cinquanta L; Ottomano C; Salvatore M; Incoronato M
    Front Immunol; 2022; 13():947187. PubMed ID: 36248864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.
    Laquintana V; Mottini C; Marchesi F; Marcozzi B; Terrenato I; Sperandio E; de Latouliere L; Carrieri F; Pimpinelli F; Pontone M; Pellini R; Campo F; Conti L; Accetta C; Mandoj C; Petrone F; Di Bella O; Vujovic B; Morrone A; Compagnone M; Principato E; Pinto E; Papa E; Falcucci P; La Malfa A; Pallocca M; De Marco F; Piaggio G; Ciliberto G; Mengarelli A; di Martino S
    Front Immunol; 2023; 14():1221587. PubMed ID: 38343436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.
    Kanji JN; Bailey A; Fenton J; Ling SH; Rivera R; Plitt S; Sligl WI; Taylor S; Turnbull L; Tipples G; Charlton CL
    Vaccine; 2021 Sep; 39(39):5563-5570. PubMed ID: 34454782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study.
    Buonfrate D; Piubelli C; Gobbi F; Martini D; Bertoli G; Ursini T; Moro L; Ronzoni N; Angheben A; Rodari P; Cardellino C; Tamarozzi F; Tais S; Rizzi E; Degani M; Deiana M; Prato M; Silva R; Bisoffi Z
    Clin Microbiol Infect; 2021 Dec; 27(12):1845-1850. PubMed ID: 34329793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study.
    Eliakim-Raz N; Stemmer A; Leibovici-Weisman Y; Ness A; Awwad M; Ghantous N; Erez N; Bareket-Samish A; Levy-Barda A; Ben-Zvi H; Moskovits N; Bar-Haim E; Stemmer SM
    BMJ Open; 2022 Aug; 12(8):e061584. PubMed ID: 35918111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccine.
    Ferrari D; Ambrosi A; Di Resta C; Tomaiuolo R; Locatelli M; Banfi G
    J Immunol Methods; 2022 Jul; 506():113293. PubMed ID: 35660546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
    Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
    Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
    Oliveira-Silva J; Reis T; Lopes C; Batista-Silva R; Ribeiro R; Marques G; Pacheco V; Rodrigues T; Afonso A; Pinheiro V; Araújo L; Rodrigues F; Antunes I
    Vaccine; 2022 Jan; 40(4):650-655. PubMed ID: 34952755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Torquetenovirus viral load is associated with anti-spike antibody response in SARS-CoV-2 mRNA BNT162b2 vaccinated kidney transplant patients.
    Querido S; Adragão T; Pinto I; Ormonde C; Papoila AL; Pessanha MA; Gomes P; Ferreira S; Figueira JM; Cardoso C; Viana JF; Weigert A
    Clin Transplant; 2022 Dec; 36(12):e14825. PubMed ID: 36301197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar.
    Bansal D; Atia H; Al Badr M; Nour M; Abdulmajeed J; Hasan A; Al-Hajri N; Ahmed L; Ibrahim R; Zamel R; Mohamed A; Pattalaparambil H; Daraan F; Chaudhry A; Oraby S; El-Saleh S; El-Shafie SS; Al-Farsi AF; Paul J; Ismail A; Al-Romaihi HE; Al-Thani MH; Doi SAR; Zughaier SM; Cyprian F; Farag E; Farooqui HH
    Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Activity and SARS-CoV-2 Vaccine mRNA Persistence in Serum and Breastmilk After BNT162b2 Vaccination in Lactating Women.
    Yeo KT; Chia WN; Tan CW; Ong C; Yeo JG; Zhang J; Poh SL; Lim AJM; Sim KHZ; Sutamam N; Chua CJH; Albani S; Wang LF; Chua MC
    Front Immunol; 2021; 12():783975. PubMed ID: 35087517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals.
    Maeda K; Amano M; Uemura Y; Tsuchiya K; Matsushima T; Noda K; Shimizu Y; Fujiwara A; Takamatsu Y; Ichikawa Y; Nishimura H; Kinoshita M; Matsumoto S; Gatanaga H; Yoshimura K; Oka SI; Mikami A; Sugiura W; Sato T; Yoshida T; Shimada S; Mitsuya H
    medRxiv; 2021 Jul; ():. PubMed ID: 34373860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.